Advocacy intelligence hub — real-time data for patient organizations
Actimmune: FDA approved
Delaying time to disease progression in patients with severe, malignant osteopetrosis.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Actimmune
Horizon Therapeutic Ireland DAC
Actimmune
(Interferon gamma 1-b)Orphan drugHorizon Therapeutic Ireland DAC
Interferon gamma [EPC]
12.1 Mechanism of Action Interferons bind to specific cell surface receptors and initiate a sequence of intracellular events that lead to the transcri...
Browse all Autosomal recessive malignant osteopetrosis news →
Paul Orchard, MD, MD
University of Minnesota Medical Center
📍 MINNEAPOLIS, MN
Paul Orchard, M.D., MD
Masonic Cancer Center, University of Minnesota
📍 MINNEAPOLIS, MN
View all Autosomal recessive malignant osteopetrosis specialists →